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Abstract
Background: The United States Preventive Services Task Force (USPSTF) issued recommendations for older, heavy
lifetime smokers to complete annual low-dose computed tomography (LDCT) scans of the chest as screening for
lung cancer. The USPSTF recommends and the Centers for Medicare and Medicaid Services require shared decision
making using a decision aid for lung cancer screening with annual LDCT. Little is known about how decision aids
affect screening knowledge, preferences, and behavior. Thus, we tested a lung cancer screening decision aid video
in screening-eligible primary care patients.
Methods: We conducted a single-group study with surveys before and after decision aid viewing and medical
record review at 3 months. Participants were active patients of a large US academic primary care practice
who were current or former smokers, ages 55–80 years, and eligible for screening based on current screening
guidelines. Outcomes assessed pre-post decision aid viewing were screening-related knowledge score (9 items
about screening-related harms of false positives and overdiagnosis, likelihood of benefit; score range = 0–9)
and preference (preferred screening vs. not). Screening behavior measures, assessed via chart review, included
provider visits, screening discussion, LDCT ordering, and LDCT completion within 3 months.
Results: Among 50 participants, knowledge increased from pre- to post-decision aid viewing (mean = 2.6 vs.
5.5, difference = 2.8; 95% CI 2.1, 3.6, p < 0.001). Preferences across the overall sample remained similar such
that 54% preferred screening at baseline and 50% after viewing; however, 28% of participants changed their
preference (to or away from screening) from baseline to after viewing. We assessed screening behavior for 36
participants who had a primary care visit during the 3-month period following enrollment. Eighteen of 36
preferred screening after decision aid viewing. Of these 18, 10 discussed screening, 8 had a test ordered, and
6 completed LDCT. Among the 18 who preferred no screening, 7 discussed screening, 5 had a test ordered,
and 4 completed LDCT.
Conclusions: In primary care patients, a lung cancer screening decision aid improved knowledge regarding
screening-related benefits and harms. Screening preferences and behavior were heterogeneous.
Trial registration: This study is registered at www.clinicaltrials.gov. NCT03077230 (registered retrospectively,November
22, 2016).
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Background
Lung cancer is the leading cause of cancer death in the
United States (US) [1]. The National Lung Screening
Trial (NLST) showed that annual low-dose computed
tomography (LDCT) can reduce mortality from lung
cancer in a high-risk population [2]. However, despite
evidence for mortality reduction, LDCT screening can
also lead to harms. For example, more than 95% of
screen-detected nodules are ultimately determined to be
benign (i.e. false positives) after follow-up evaluation,
which can be costly and invasive [2]. Further, screening
can also lead to the detection and unnecessary treatment
of cancers that would not have affected the patient clin-
ically in his/her lifetime (overdiagnosis) [3, 4].
Based on NLST findings and other evidence [5, 6], the
US Preventive Services Task Force (USPSTF) found that
there was sufficient support for the net benefit of screen-
ing to recommend annual screening with LDCT for
patients ages 55–80 with 30 or more pack-years smoking
history who have smoked in the past 15 years [4]. Because
of the tradeoffs between benefits and harms involved,
guidelines recommend a thorough process of informed
and shared decision-making occur prior to commencing
annual screening. [4, 7] However, experts remain con-
cerned that widespread implementation of screening
could happen without patients being appropriately
informed [8]. These concerns are supported by accumu-
lating evidence that US patients generally overestimate the
benefits and are poorly informed about the potential
harms of cancer screening [9–14]. These concerns in-
formed a 2015 Centers for Medicare & Medicaid Services
(CMS) coverage decision requiring that a “shared
decision-making visit” involving the use of a patient deci-
sion aid be conducted before screening would be covered
for CMS beneficiaries [15, 16].
Decision aids are evidence-based tools designed to fa-
cilitate informed and shared decision-making about
complex treatments or screening choices [17]. A lung
cancer screening decision aid may be a helpful adjunct
in conveying the complex information about benefits
and harms of screening. However, few lung cancer
screening decision aids have been tested and, to our
knowledge, none have been studied in a primary care
setting, where cancer screening decisions typically take
place [18–20]. Moreover, little is known about whether
decision aids help screening-eligible patients develop a
realistic understanding of the likelihood of benefitting
from screening or improve their understanding of im-
portant but difficult to understand screening-related
harms, such as false positives and overdiagnosis [18, 19].
Methods
We report the findings from a single-group primary care
clinic-based study of a video decision aid on lung cancer
screening in a cohort of screening-eligible primary care
patients. We had three main study aims: first, to assess
the effect of the decision aid on knowledge of the bene-
fits and harms of screening and on screening prefer-
ences; second, to describe screening behavior within
3 months of viewing a screening decision aid; and third,
to examine relationships between screening knowledge,
preferences, and screening test ordering during subse-
quent primary care encounters.
Setting and participants
The study setting was an academic internal medicine
practice serving approximately 13,000 patients. We identi-
fied active patients who were current or former smokers
ages 55–80. We excluded patients with lung cancer, can-
cer treatment with chemotherapy or radiation within
18 months, recent hemoptysis or unexplained weight loss,
or any chest CT within 18 months. Study staff reviewed
electronic health records (EHR) and further excluded
those who clearly did not meet USPSTF smoking history
requirements (i.e. fewer than 30 pack-years or quit more
than 15 years ago). Primary providers reviewed lists of
their potentially eligible patients and excluded those
deemed inappropriate for screening based on comorbidi-
ties. Approved patients were mailed a recruitment packet
containing a study invitation letter and an opt-out card.
Patients then received a recruitment telephone call
where an eligibility survey was administered to confirm
screening eligibility based on USPSTF guidelines. Eligible
patients who agreed to participate were scheduled for a
study visit at the clinic. Upon arrival and consent, partic-
ipants completed a baseline survey, viewed the video
decision aid, and completed a follow-up survey. Screen-
ing behaviors were assessed via EHR review at 3 months.
Participants received a $40 gift card. Data were collected
from October 2015–October 2016 and analyzed from
October 2016–February 2017.
Intervention
We previously developed and refined the decision aid
based on feedback from screening-eligible patients
from the community (n = 11) and providers from the
academic medical center (n = 11) [21]. The decision
aid was designed to meet requirements specified by
CMS and relevant standards set by the International
Patient Decision Aid Standards Collaboration, and to
be accessible to those with low literacy [15, 22]. Writ-
ten text was read aloud, and technical terms and con-
cepts were explained using narration, graphics, and
animations. We pre-tested the decision aid and mea-
sures with 10 screening-eligible participants before
beginning the pre-post phase of the study.
Content included the rationale for screening, eligi-
bility criteria, a description of the LDCT procedure,
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and a dynamic icon array (pictogram) that sequen-
tially depicted estimates for benefits and harms of
screening among 1000 individuals screened annually
for 3 years (Fig. 1). Estimates were based on NLST
trial data as presented in materials developed by the
National Cancer Institute and the Veterans Health
Administration (VHA) [2, 20, 23, 24]. Benefits pre-
sented in the pictogram were lung cancer deaths
averted (3 per 1000 screened). Harms presented in-
cluded false positives, need for biopsy that did not
find cancer, serious complications from biopsies, and
overdiagnosis. Other potential screening harms, pre-
sented qualitatively (not in the pictogram) included
radiation exposure, anxiety and distress, and costs re-
lated to follow-up tests and procedures. The video
concluded with an implicit values clarification exercise
prompting the viewer to weigh the potential benefits
and harms of screening and discuss them with his/her
doctor. Participants viewed the 6-min video at the
clinic on a tablet computer (available online https://
goo.gl/1f7XIY).
Measures
Knowledge
We measured screening-related knowledge before and
after decision aid viewing (items shown in Results,
Table 2). Knowledge of benefit was assessed using a sin-
gle item asking about the number of lung cancer deaths
averted per 1000 individuals screened. Response options
including contiguous estimates ranging from 0 up to
1000. Because our primary goal was to convey the “gist”
concept that the number of individuals who benefit is
small relative to the number of individuals screened, we
treated responses that were within an order of magni-
tude of the value presented in the decision aid, i.e. up to
30 per 1000, as correct. Knowledge of harms was
assessed using seven items adapted from a previously-
published overdiagnosis knowledge scale [25] and one
item about false positives. Knowledge items were catego-
rized as either correct or incorrect, with “don’t know”
responses treated as incorrect. A knowledge score was
calculated (0–9 points) by summing the correct answers.
Preference
Screening preference was assessed through a single 5-
point Likert item adapted from a previous study asking
participants how much they agreed with the statement
“I plan to have a lung cancer screening test in the near
future” (strongly agree to strongly disagree) [26].
Clinical screening behavior and LDCT findings
For patients who had a primary care visit, we assessed
whether there was EHR documentation of each of the
following: screening-related discussion, LDCT order, and
LDCT completion. For completed CTs, we also recorded
the LungRADS nodule classification based on the radiol-
ogist’s report [27].
Decision aid acceptability
We assessed decision aid acceptability using a published
scale measuring perception of decision aid length, bal-
ance, and suitability for decision-making [28].
Statistical analyses
We characterized the study population with descriptive
statistics. We tested for pre-post changes in knowledge
using a paired t-test for total score and McNemar’s chi-
squared tests for individual items. We dichotomized the
preference item, defining “preference for screening” as
“agree” or “strongly agree” responses. We calculated the
proportions who changed their preference before and
after decision aid viewing. We calculated proportions for
screening behavior measures and LDCT findings among
participants who had a provider visit after viewing the
decision aid (and thus an opportunity for screening dis-
cussion and test ordering). We examined the relationship
Fig. 1 Decision aid screenshots
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between (post-decision aid) knowledge and screening
preference using logistic regression controlling for
baseline preference. We also calculated the proportion
of visits with a “preference concordant” decision, de-
fined as either: preferring screening and having LDCT
ordered, OR not preferring screening and not having
an LDCT ordered. Analyses were conducted using
STATA (Release-13, College Station, TX).
Results
Enrollment (see Fig. 2): We mailed 716 recruitment let-
ters and reached 378 patients by telephone. Among 215
patients who completed the initial eligibility assessment,
135 were found ineligible. Common reasons for declin-
ing to complete the eligibility assessment included poor
health, lack of time, and transportation challenges. Among
the 80 patients initially found eligible for the study, 18
either declined participation or did not attend the study
visit. Of the 62 (78%) eligible patients who participated, 10
completed the pre-test phase and thus were ineligible to
participate in the main pre-post phase. Two additional
participants were later found to be ineligible during the
follow-up chart review phase of the study (because of re-
cent chest CTs) and were excluded from analysis. The
final analytic sample included 50 participants.
Sample characteristics (Table 1) include: mean age of
63 years; 48% female; 58% White; 30% Black; 12% other
race; 50% high school education or less; 46% current
smokers; average of 52 pack-years smoked; 40% COPD;
and 56% had Medicare (alone or with another
insurance).
Screening knowledge and preferences
Knowledge score (9-point scale) increased after viewing
the decision aid from 2.6 to 5.5 (difference = 2.8; 95%
confidence interval [CI] 2.1, 3.6, p < 0.001) (Table 2). Be-
fore decision aid viewing, the most common response
was that 401–700 individuals benefit per 1000 screened.
After decision aid viewing, the most common response
category was 1–5 per 1000. In the overall sample, 27
(54%) participants preferred screening at baseline and 25
(50%) preferred screening after viewing.
Of the 27 participants who preferred screening pre-
decision aid viewing, 8 (30%) changed and did not prefer
screening after viewing. Of the 23 participants who did
716 Current/
Former Smokers
378 Reached 
by Phone
338 Not 
Reached
163 Declined 
Eligibility 
Assessment
135 Ineligible
215 Assessed 
for Eligibility
9 Declined to 
Participate
9 No Show
10 Pre-test 
Participants
2 Excluded*
80 Eligible
62 
Participated
50 Included in 
Analysis
*found to be ineligible during 
follow-up chart review
Fig. 2 Flowchart of enrollment
Table 1 Participant Characteristics (n = 50)
Average or %
Age 63
Sex (% Female) 48%
Race/Ethnicity
White 58%
Black 30%
Other 12%
Education
≤ 12 years 50%
Smoking status (% current) 46%
Pack-years smokeda 52
COPD 40%
Insurance Status
No insurance 8%
Private insurer (only) 28%
Medicare (only) 30%
Medicaid (only) 8%
Medicare, plus other insurer 26%
a(average packs per day * years smoked)
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not prefer screening pre-decision aid, 6 (26%) preferred
screening post-decision aid.
We observed an inverse relationship between post-
decision aid knowledge and screening preference (odds
ratio = 0.73; 95% CI 0.54, 0.98; p = 0.03). For each point in-
crease in post-decision aid knowledge score there was an
estimated 27% reduction in the odds of preferring
screening.
Decision aid acceptability
Most participants (n = 48, 96%) reported that the deci-
sion aid was “useful in making a decision about getting
screened for lung cancer.” Most participants (n = 29,
58%) felt that the decision aid was balanced, 16 (32%) in-
dicated that it was slanted toward getting screened, and
5 (10%) indicated that it was slanted toward no
screening.
Screening behavior
Thirty-six participants had a clinic visit in the 3 months
following study enrollment (Fig. 3), among whom 21
(58%) had concordance between test preference and test
ordering. Among 18 participants preferring screening
after decision aid viewing, 10 (56%) discussed screening,
8 (44%) had a test ordered, and 6 (33%) completed
LDCT. Among the 18 not preferring screening, 7 (39%)
discussed screening, 5 (28%) had a test ordered, and 4
(22%) completed LDCT. Discordance was greatest for
the 18 participants who indicated they preferred screen-
ing, of whom 10 did not subsequently have an LDCT
ordered. Notably, in 8 of these 10 cases, there was no
apparent screening discussion with the provider.
LDCT findings
Among the 10 completed LDCTs, 7 were LungRADS cat-
egory 1 (normal result) and 2 were category 2 (small nod-
ules, benign appearance). One was category 4a (suspicious
findings); this participant preferred screening in the study
and the recommended 3-month follow-up scan showed
resolution of the nodule.
Discussion
We report findings from testing a lung cancer screening
decision aid in 50 primary care patients. We found that
decision aid viewing was associated with greater know-
ledge of the benefits and harms of screening. At baseline,
we found that participants tended to greatly overesti-
mate the chances of benefitting from screening. After
viewing, participants tended to have a more realistic
understanding of the chances of benefitting. We also
found that decision aid viewing led to improved under-
standing of two important but conceptually complex
screening-related harms: false positives and overdiagno-
sis. To our knowledge, this study is the first to
Table 2 Changes in knowledge and intent to initiate lung cancer
screening before and after viewing the decision aid (n = 50)
Pre Post Difference
(95% CI), p-value
Potential Harms of Screening
Who do you think is more likely to
be diagnosed with lung cancer?
People who are screened for lung cancer.a
People who are NOT screened for
lung cancer
36% 62% 26% (8%, 44%),
p < 0.001
ALL lung cancers will eventually cause
illness and death if they are not found
and treated.
True/Falsea/Don’t Know
6% 54% 48% (31%, 65%),
p < 0.001
When screening finds lung cancer,
doctors can tell whether the cancer
will ever cause harm.
True/Falsea/Don’t Know
16% 62% 46% (62%, 30%),
p < 0.001
Even lung cancers that may not cause
any health problems are likely to be
treated.
Truea/False/Don’t Know
66% 80% 14% (4%, 32%),
p = 0.09
Screening tests lead some people to
get cancer treatments that they do
not need.
Truea/False/Don’t Know
18% 76% 58% (40%, 76%),
p < 0.001
Screening tests find harmless lung
cancers about as often as they
prevent death from lung cancer.
Truea/False/Don’t Know
24% 52% 28% (9%, 47%),
p < 0.001
Which of these 2 statements best
describes over-detection from
screening?
Screening finds a cancer that would
never have caused troublea
Screening finds an abnormality but
extra tests show it is not cancer
16% 28% 12% (3%, 27%),
p = 0.08
An abnormal result from lung cancer
screening always means the person
has lung cancer.
True/Falsea/Don’t Know
66% 88% 22% (5%, 39%),
p < 0.001
Chances of Benefitting from Screening
For the next question, please think
about 1000 current and former smokers
who are getting screened every year for
lung cancer. Out of 1000 people who
get a chest CT scan, about how many
will have their lives prolonged?
0
1-5a
6-10a
11-30a
31–100
101–200
201–400
401–700
701–1000
Don’t Know
18% 48% 30% (12%, 48%),
p < 0.001
Average Knowledge Score
(0–9 points)
2.6 5.5 2.8 (2.1,3.6),
p < 0.001
aCorrect response(s)
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demonstrate that viewing a decision aid can help attenu-
ate biased perceptions about the benefits and harms of
lung cancer screening.
Our study complements and extends a limited body
of empiric evidence about lung cancer screening deci-
sion aids. Previous studies were conducted in popula-
tions recruited from the community [19], or referral
settings such as a tobacco cessation clinic [18] or a
dedicated, sub-specialty screening program [20]. Our
study was conducted in a primary care setting and
allowed providers to exclude patients they believed to
be poor screening candidates based on co-morbidity
concerns. Thus, despite being relatively small, our
study mimicked a systematic, practice-based approach
to screening. Furthermore, two of three prior studies
tested lung cancer screening decision aids in mixed
populations that included relatively small numbers
of screening eligible patients (n = 14 and n = 11,
respectively) [18, 19]. All participants in our study
were eligible for screening based on current USPSTF
guidelines.
We found that baseline (pre-decision aid) screening
preferences were heterogeneous, with roughly half of
participants falling into each of our two preference
groups (preferring screening vs. not). Although decision
aid viewing was not associated with net changes in the
proportions in each of these preference groups in the
overall study sample, about one-quarter of participants
in each group actually changed their screening prefer-
ence after decision aid viewing (in opposite directions).
Our findings suggest that we cannot assume screening-
eligible primary care patients will be uniformly inclined
toward or away from screening. Moreover, our results
also suggest that a non-trivial proportion of primary care
patients may change their preferences as they become
more informed about screening.
Our results are consistent with the findings of
Kinsinger et al.’s VHA pragmatic screening demonstra-
tion pilot [29] in that we observed heterogeneity in
screening behavior. Among participants who preferred
screening and saw a provider within 3 months of deci-
sion aid viewing, about half discussed LDCT scanning
with their provider and about a third completed an
LDCT. We also found that some participants who did
not prefer screening after decision aid viewing ended up
completing an LDCT. Kinsinger et al. similarly found
that 50% of eligible patients completed screening [29].
While the VHA demonstration program developed and
utilized paper-based decision support materials (from
which we adapted our video decision aid), no data are
available regarding the manner and extent to which they
were used.
Our findings that 50% of patients preferred screen-
ing post-decision aid and 28% completed screening (among
patients with post-decision aid primary care encounters),
contrasts with findings from what is, to our knowledge, the
only other study to assess screening completion in individ-
uals receiving a lung cancer screening decision aid. That
study, conducted by Mazzone et al. in patients attending a
tertiary screening program, found that 95% of participants
completed screening after undergoing a shared decision
making visit [20]. We hypothesize that the overwhelming
majority of patients who attend a dedicated lung cancer
screening program assume that the purpose of referral to
such a program is to complete screening, rather than to de-
cide about screening. When considering Mazzone’s findings
alongside our results, it suggests that the time frame during
which screening-eligible patients actually make decisions
about screening is before they attend a dedicated screening
program. Tertiary lung cancer screening programs are now
being implemented in the US, and many claim to be able to
conduct shared decision making. Our findings add to the
50 Participated 
in Study
36 Had Visit 
within Three 
Months
14 No Visit 
within Three 
Months
18 Preferred 
Screening
10 Had Screening 
Discussion
8 CT Ordered
6 Screened
18 Did Not Prefer 
Screening 
7 Had Screening 
Discussion
5 CT Ordered
4 Screened
LungRADS
Category 1 = 7
Category 2 = 2
Category 4a = 1
Fig. 3 Flowchart of lung cancer screening decisions and behavior
among study participants
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discourse regarding the appropriate implementation context
for medical decision making about lung cancer screening.
We found that the more knowledge participants
had about benefits and harms of screening, the less
likely they were to prefer screening. The fact that we
did not observe differences in screening behavior sug-
gests the need for additional research aimed at under-
standing how we can help ensure that patients
receive care that is consistent with their preferences.
This will likely require interventions beyond providing
patient decision aids.
Our study examined decision aid effects on knowledge
about two important harms of screening: overdiagnosis
and false positives. We chose these outcomes because:
1) overdiagnosis and false positive tests can cause sub-
stantial harms in screened populations; 2) CMS explicitly
requires that information about overdiagnosis and false
positives be included in lung cancer screening decision
aids; and 3) these harms may not be recognized or
understood by patients making medical decisions about
cancer screening [9, 15, 25]. Other knowledge domains
are also probably relevant to decisions about lung cancer
screening [8]. Further research is needed to assess the
validity of measures of decision-relevant knowledge and
to better understand knowledge thresholds at which pa-
tients may be considered adequately informed to make
medical decisions about cancer screening.
We found relatively low concordance (58%) between
(post-decision aid) preferences and LDCT ordering
during subsequent provider visits. It appears that a
major driver of discordance was that many patients
who preferred screening and did not have an LDCT
ordered did not actually have an opportunity to dis-
cuss screening with their provider. This finding points
to an important problem in implementation of patient
decision support in health care. Decision aids are
intended not to replace but to inform discussions be-
tween patients and providers about medical decisions
[30, 31]. However, competing demands and lack of
adequate provider time to deliver preventive services
are important barriers to effective communication and
decision-making [16]. Further, lung cancer screening
is especially complex given both the risk for lung
cancer in this population and the chances of serious
complications as a consequence of screening. Thus,
further research is needed to understand how best to
structure lung cancer screening decision support in-
terventions in the primary care medical home to en-
sure that there is adequate time for patients and
providers to discuss and deliberate. Moreover, more
research is needed to understand the role that do-
mains other than knowledge and stated preferences
play in the complex picture of lung cancer screening
behavior.
Limitations
Our study has limitations. First, because of the one-
group, pre-post study design we were unable to compare
the effects of the decision aid with usual care. Second,
this was a single site study and many patients declined
initial eligibility assessment. Additionally, patients re-
ceived an incentive to participate and were required to
attend a separate study visit, both of which can affect
participant behavior and sample representativeness.
Thus, the degree to which the findings are generalizable
to other screening-eligible populations is unclear. Never-
theless, our participants were similar to NLST partici-
pants in terms of average age (63 in our study, 62 in
NLST), pack-years smoked (52 vs. 56, respectively), per-
cent current smokers (46% vs. 48%, respectively), and
percent female (48% vs 41%, respectively) [32]. Our sam-
ple reflects a more disadvantaged population than was
studied in the NLST in that they were less likely to be
white (58% vs 91%, respectively) and less likely to have
received education beyond high school (50% vs 70%, re-
spectively) [33]. Third, knowledge was assessed immedi-
ately following completion of the decision aid and may
not reflect long-term retention of lung cancer screening
information. Finally, our behavior assessments were rela-
tively crude in that we did not differentiate between
chest CT scans discussed and ordered for diagnostic rea-
sons (i.e. to evaluate symptoms) vs. for true screening.
Another consideration is that the decision aid we
tested was not targeted to lung cancer risk. Ideally, infor-
mation about benefits and harms of screening would be
tailored to the patient’s individual lung cancer risk, as
occurs in the decision aid produced at the University of
Michigan [33]. However, brief video decision aids such
as ours or the one developed by Volk and colleagues
[18] do not require high-level reading capability, entry of
patient-specific data, or other interaction by the patient.
Such a format offers potential advantages in terms of
implementation, and may be better suited for low-
literacy populations. Studies are needed to examine
tradeoffs associated with using simpler versus more
complex, tailored decision aids for lung cancer screen-
ing, particularly given the prevalence of low education
and low literacy in the US screening-eligible population.
Conclusions
We found that, among primary care patients who are
eligible for lung cancer screening based on USPSTF
guidelines, viewing a lung cancer screening decision aid
improved screening-related knowledge. It gave patients a
more realistic perception of the likelihood of benefit. It
also gave them a greater understanding of the nature of
important screening-related harms. Our findings, al-
though preliminary, suggest that a non-trivial proportion
of screening-eligible patients may change their screening
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preferences after decision aid viewing. In contrast to
findings in a referral population at a tertiary, sub-
specialty screening program, screening preferences and
behaviors among screening-eligible patients in a primary
care population appear to be heterogeneous.
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